Lost in all the noise created over the government shutdown is the fact that President Donald Trump just made hemp legal in all 50 states.
The 2018 Farm Bill Trump now signed allows for hemp cultivation and the transfer of hemp-derived products across state lines for commercial or other purposes. In anticipation of the development, a broad group of cannabis and CBD companies are preparing for adoption with efforts to fill the new demand for product including Aurora Cannabis (TSX: ACB) (OTC: ACBFF), Cronos Group (NASDAQ: CRON), and AmeriCann, Inc. (OTC: ACAN).
With this news in hand, the CBD products sector is expected to grow in leaps and bounds. One early aggregator taking the initiative is The Yield Growth Corp., which holds varied interests. The Yield Growth Corp. (CSE:BOSS) has developed a line of wellness and beauty products that take advantage of what the hemp plant can offer legally, as well as offering the opportunity to infuse products with THC or CBD wherever they become legal. The combination is paving the way for strong growth in the burgeoning market.
The changing landscape for CBD
Now that Jeff Sessions is no longer the U.S. Attorney General, the Feds have taken the bold steps to remove all restrictions on the sale, transport, or possession of hemp-derived products produced in a manner consistent with the law. This means life for sellers of Cannabidiol, better known as CBD, just got a huge boost.
Sessions it seems was one of the Trump Administration's biggest opponents to legal marijuana and without this roadblock, the opportunity for hemp and CBD is rife.
For a fact check, both hemp and marijuana are Cannabis plants. The difference is that hemp has less than 0.3% of THC, the psychoactive chemical that creates a high. On the other hand, marijuana has between 5-35% of THC with obvious attributes.
Hemp has a whole stack of industrial uses that date back a long time and can be found in food, clothing, body care products and even plastics and automobiles. One of its growing uses is for the extraction of CBD oil, another chemical in the plant that has indicated medicinal purposes, but doesn't create the high that gives a negative stigma to marijuana use.
Big things ahead for CBD and hemp
People claim that CDB can treat ailments from anxiety, depression, and stress to insomnia, muscle inflammation, joint pain, and more. No surprisingly, the cannabis industry isn't just selling marijuana in states where it's legal. CBD, which is put into oils, lotions and foods, has already become a significant source of revenue for the industry in states where marijuana remains illegal.
A first-mover that anticipated this change is The Yield Growth Corp., whose unique approach aims to sell its base products nearly anywhere in the world, and then capitalize on markets that legalize recreational use of THC or CBD. In this way, they are opening new markets with the legalization as a pathway to larger market share.
The Yield Growth Corp. has multiple major brands to provide a broad portfolio in the developing CBD space. Under the brand Urban Juve, they currently have a set of nearly 50 different products launching in 2019. The initial launch will consist of base products only.
Along with its own efforts, The Yield Growth Corp. also has granted CROP Infrastructure Corp., –which grows, produces, and sells cannabis products– the rights to distribute Urban Juve products in Italy. CROP has a strong base in California, Nevada, and Washington State, and have recently expanded into Jamaica to capitalize on the ideal growing conditions there.
Strong support is creating really impressive growth
The new law signed in by Trump means the makers of CBD products can buy raw materials across state lines and sell their products without the threat of legal issues. Equally important, the Farm Bill lets hemp growers apply for federal crop insurance and allows CBD product makers and sellers to receive financial services from banks and credit card processing companies. This is critical to business, as the inability to do non-cash financial transactions has been one of the hurdles that hamstrung the industry.
Many businesses support the sale of this newly legal product. They range from small to large businesses and there is a strong consensus on how the future looks with the Farm Bill signed. Ron Smalley Jr. who runs Vista Green Group, a consulting firm based in Portland, Maine put the cannabis and CBD market in perspective.
"In the near future, there is a great opportunity for the products controlling the raw materials and the processing of raw materials," said Smalley. "Right now, we're seeing a bottleneck in processing, and it costs millions to bring on new products. There are plenty of farmers, it's the bottleneck of processing holding things back. Over the next 12 months you’ll see huge growth in the hemp industry ..."
Cannabis producers already moving on new brands and increased supply to CBD and hemp markets may benefit greatly from the opening of these new markets. These include:
Aurora Cannabis (TSX: ACB) (OTC: ACBFF) has funded capacity in excess of 430,000 kg per year and operations across Canada and in Europe, making it is one of the world's largest cannabis companies. The Company is vertically integrated and horizontally diversified across every key segment of the value chain.
Cronos Group (NASDAQ: CRON) is hoping to grow through providing medical marijuana to international markets. The company has an exclusive cannabis supply agreement with Pohl-Boskamp, which distributes products to more than 12,000 pharmacies in Germany. Cronos is participating in a joint venture to supply medical marijuana to Australia, New Zealand, and Southeast Asia.
AmeriCann, Inc. (OTC: ACAN) develops, owns and supports advanced medical cannabis cultivation and processing facilities nationwide. The Company has a multi-market portfolio of over 1,000,000 square feet of sustainable cannabis production infrastructure in various stages of development.
For a more information about The Yield Growth Corp. and legal hemp and CBD businesses see the article at: http://equity-insider.com/2018/12/09/beauty-and-cosmetic-stocks-in-2019/
Equity-Insider
http://equity-insider.com
[email protected]
Legal Disclaimer/Disclosure:
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for The Yield Growth Company (“TYGC”) advertising and digital media from the company. There may be 3rd parties who may have shares of BOSS and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. The owner/operator of MIQ has purchased shares of BOSS through a private placement and does not intend on selling any shares within 72 hours of this updated publication date (December 6, 2018) after such point we reserve the right to buy and sell shares in the open market, no further notice will be given. We also expect further compensation from the company and will partake in future private placements of BOSS as an ongoing effort to gain exposure for the company. No further notice will be given, but let this serve as notice that we are not independent in our opinion and this is a major conflict of interest as to our ability to remain objective in our communication. Always consult a licensed financial advisor before making any sort of investment decision. Due to the volatility of the capital markets, and especially those that are thinly traded at lower prices, it is very easy to lose some, if not all, of your investment. Caution needs to be taken when making any sort of investment decision.
By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing MIQ, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
